Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136422 · ClinicalTrials.gov registry record · Phase 1
Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia
A Phase 1 study of Acute Myelogenous Leukemia and Myelodysplasia, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00136422 is a Phase 1 study of Acute Myelogenous Leukemia and Myelodysplasia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants, below the 139-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00136422, a Phase 1 study of Acute Myelogenous Leukemia and Myelodysplasia, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety of a new investigational acute myeloblastic leukemia (AML) vaccine and see what effects (good and bad) it has on patients with advanced myelodysplasia or acute myelogenous leukemia.
Conditions Studied
Interventions
- BIOLOGICAL autologous tumor cells
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2000-01 |
| Est. Completion | 2006-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00136422
The ClinicalTrials.gov registry entry for NCT00136422 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 139-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (78% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Myelogenous Leukemia appearing as the primary indexed condition, and to 1 intervention - of which autologous tumor cells is the first listed.
NCT00136422 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00136422 about?
NCT00136422 is a clinical study titled "Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia". The purpose of this study is to test the safety of a new investigational acute myeloblastic leukemia (AML) vaccine and see what effects (good and bad) it has on patients with advanced myelodysplasia or acute myelogenous leukemia.
What is the current status of trial NCT00136422?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2000-01. Estimated completion is 2006-03.
What conditions does trial NCT00136422 study?
This clinical trial studies the following conditions: Acute Myelogenous Leukemia, Myelodysplasia.
What interventions are being tested in trial NCT00136422?
The interventions under investigation include: autologous tumor cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00136422?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00136422 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myelogenous Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
RECRUITING · Phase 1
-
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
ACTIVE NOT RECRUITING · Phase 1
-
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
COMPLETED · Phase 1
-
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.